CD274 and non-small cell lung carcinoma: Indeed, PD‐L1 levels predict the response rate, as well as the progress‐free survival (PFS) or overall survival (OS) benefit, for specific PD‐1 monoclonal antibodies, alone or with chemotherapy, in treating NSCLC.14